SecBot SecBot
DEFA14A ·Filed May 21, 2026

FONR

FONAR CORP
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001193125-26-234921
Proxy solicitation materials
Actionable Insight • Neutral

The merger vote is one week away. Monitor for shareholder approval and any last-minute legal challenges. The supplemental disclosures reduce litigation risk but do not alter the merger price or likelihood of completion.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+5d ⚠ clustered
FONR ▲ +1.14% at T+5d
NEUTRAL call +1.14% · α vs SPY -0.52% · entry $18.90 → $19.11
Next anchor: T+20d due 4mo ago
Entry = T+0 close
May 21, 2026
via day close
T+1d
+0.08%
call +0.08% · α -0.51%
$18.91
settled 5mo ago
T+5d
+1.14%
call +1.14% · α -0.52%
$19.11
settled 5mo ago
T+20d
Pending
due 4mo ago
T+60d
Pending
due 2mo ago

Price Chart

Loading chart...

Executive Summary

FONAR filed additional definitive proxy materials to supplement disclosures for its planned going-private merger, responding to stockholder lawsuits alleging deficient disclosures. The special meeting to vote on the merger is scheduled for May 28, 2026. The supplemental disclosures include timeline details, confirmation that non-disclosure agreements did not contain 'don't ask-don't waive' standstills, and additional financial projections from Marshall & Stevens.

Key Financial Metrics

Vote
merger approval
Meeting
2026-05-28

Key Facts

  • Special meeting to vote on merger scheduled for May 28, 2026.
  • Company voluntarily supplements proxy statement in response to lawsuits alleging deficient disclosures.
  • No new financial terms of the merger are disclosed.
  • Marshall & Stevens estimated liquidation value of common equity at approximately $14.63 per share.
  • CEO Timothy Damadian controls the buyer entities, creating a potential conflict of interest.

Financial Impact

No new financial magnitude; supplemental disclosures do not change merger consideration.

Risk Factors

  • Shareholders may reject the merger despite supplemental disclosures.
  • Litigation could still delay or block the transaction.
  • Management conflict of interest (CEO buying out public shareholders, no competing bids solicited).

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-234921
Document: 0001193125-26-234921-index-headers.html0001193125-26-234921
Document: 0001193125-26-234921-index.html0001193125-26-234921
Document: 0001193125-26-234921.txt0001193125-26-234921
6 reports for FONR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FONR — sortable, filterable
TypeNow
Jun 15, 2026
19w ago
15-12G
BEARISH ★ 7/10
—awaiting T+5——
Jun 3, 2026
20w ago
8-K
NEUTRAL ★ 7/10
$19.09awaiting T+5——
May 21, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%—
May 21, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%—
May 12, 2026
23w ago
DEFA14A
BEARISH ★ 7/10
$18.86 $18.86· 0.00%▼ −1.16%—
May 12, 2026
23w ago
8-K
BEARISH ★ 6/10
$18.86 $18.86· 0.00%▼ −1.16%—
Showing 6 of 6

US Market Status

Market Closed — Opens in 7h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026